276 related articles for article (PubMed ID: 26298811)
21. Immunophilins and HIV-1 V3 loop for structure-based anti-AIDS drug design.
Andrianov AM
J Biomol Struct Dyn; 2009 Feb; 26(4):445-54. PubMed ID: 19108583
[TBL] [Abstract][Full Text] [Related]
22. A single residue within the V5 region of HIV-1 envelope facilitates viral escape from the broadly neutralizing monoclonal antibody VRC01.
Guo D; Shi X; Arledge KC; Song D; Jiang L; Fu L; Gong X; Zhang S; Wang X; Zhang L
J Biol Chem; 2012 Dec; 287(51):43170-9. PubMed ID: 23100255
[TBL] [Abstract][Full Text] [Related]
23. Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120.
Andrianov AM; Kashyn IA; Tuzikov AV
J Mol Model; 2017 Jan; 23(1):18. PubMed ID: 28050723
[TBL] [Abstract][Full Text] [Related]
24. Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12.
Sterjovski J; Churchill MJ; Ellett A; Wesselingh SL; Ramsland PA; Gorry PR
Virology; 2012 Oct; 432(2):394-404. PubMed ID: 22818780
[TBL] [Abstract][Full Text] [Related]
25. Prediction of HIV-1 entry inhibitors neomycin-arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure.
Berchanski A; Lapidot A
Biochim Biophys Acta; 2007 Sep; 1768(9):2107-19. PubMed ID: 17560540
[TBL] [Abstract][Full Text] [Related]
26. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope.
Darbha R; Phogat S; Labrijn AF; Shu Y; Gu Y; Andrykovitch M; Zhang MY; Pantophlet R; Martin L; Vita C; Burton DR; Dimitrov DS; Ji X
Biochemistry; 2004 Feb; 43(6):1410-7. PubMed ID: 14769016
[TBL] [Abstract][Full Text] [Related]
27. The glycan-mediated mechanism on the interactions of gp120 with CD4 and antibody: Insights from molecular dynamics simulation.
Zhang Y; Niu Y; Tian J; Liu X; Yao X; Liu H
Chem Biol Drug Des; 2017 Dec; 90(6):1237-1246. PubMed ID: 28632942
[TBL] [Abstract][Full Text] [Related]
28. The antigenic structure of the HIV gp120 envelope glycoprotein.
Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
[TBL] [Abstract][Full Text] [Related]
29. Design, synthesis, and evaluation of HIV-1 entry inhibitors based on broadly neutralizing antibody 447-52D and gp120 V3loop interactions.
Senapathi J; Bommakanti A; Vangara S; Kondapi AK
Bioorg Chem; 2021 Nov; 116():105313. PubMed ID: 34517280
[TBL] [Abstract][Full Text] [Related]
30. Study of antibody repertoires to the CD4 binding site of gp120 of a Chinese HIV-1-infected elite neutralizer, using 454 sequencing and single-cell sorting.
Li D; Wang Z; Ren L; Zhang J; Feng G; Hong K; Hao Y; Qi Z; Liang H; Shao Y
Arch Virol; 2016 Apr; 161(4):789-99. PubMed ID: 26671829
[TBL] [Abstract][Full Text] [Related]
31. Designed cyclic permutants of HIV-1 gp120: implications for envelope trimer structure and immunogen design.
Saha P; Bhattacharyya S; Kesavardhana S; Miranda ER; Ali PS; Sharma D; Varadarajan R
Biochemistry; 2012 Mar; 51(9):1836-47. PubMed ID: 22329717
[TBL] [Abstract][Full Text] [Related]
32. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
33. A non-canonical binding interface in the crystal structure of HIV-1 gp120 core in complex with CD4.
Duan LW; Zhang H; Zhao MT; Sun JX; Chen WL; Lin JP; Liu XQ
Sci Rep; 2017 Apr; 7():46733. PubMed ID: 28429756
[TBL] [Abstract][Full Text] [Related]
34. Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.
Rosen O; Chill J; Sharon M; Kessler N; Mester B; Zolla-Pazner S; Anglister J
Biochemistry; 2005 May; 44(19):7250-8. PubMed ID: 15882063
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry.
Ugwu-Korie N; Quaye O; Wright E; Languon S; Agyapong O; Broni E; Gupta Y; Kempaiah P; Kwofie SK
Molecules; 2023 Jan; 28(2):. PubMed ID: 36677538
[TBL] [Abstract][Full Text] [Related]
36. Computation-guided backbone grafting of a discontinuous motif onto a protein scaffold.
Azoitei ML; Correia BE; Ban YE; Carrico C; Kalyuzhniy O; Chen L; Schroeter A; Huang PS; McLellan JS; Kwong PD; Baker D; Strong RK; Schief WR
Science; 2011 Oct; 334(6054):373-6. PubMed ID: 22021856
[TBL] [Abstract][Full Text] [Related]
37. Free Energy Perturbation Calculation of Relative Binding Free Energy between Broadly Neutralizing Antibodies and the gp120 Glycoprotein of HIV-1.
Clark AJ; Gindin T; Zhang B; Wang L; Abel R; Murret CS; Xu F; Bao A; Lu NJ; Zhou T; Kwong PD; Shapiro L; Honig B; Friesner RA
J Mol Biol; 2017 Apr; 429(7):930-947. PubMed ID: 27908641
[TBL] [Abstract][Full Text] [Related]
38. Structural Analysis of the Glycosylated Intact HIV-1 gp120-b12 Antibody Complex Using Hydroxyl Radical Protein Footprinting.
Li X; Grant OC; Ito K; Wallace A; Wang S; Zhao P; Wells L; Lu S; Woods RJ; Sharp JS
Biochemistry; 2017 Feb; 56(7):957-970. PubMed ID: 28102671
[TBL] [Abstract][Full Text] [Related]
39. Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors.
Ohashi N; Harada S; Mizuguchi T; Irahara Y; Yamada Y; Kotani M; Nomura W; Matsushita S; Yoshimura K; Tamamura H
ChemMedChem; 2016 Apr; 11(8):940-6. PubMed ID: 26891461
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.
Saphire EO; Parren PW; Pantophlet R; Zwick MB; Morris GM; Rudd PM; Dwek RA; Stanfield RL; Burton DR; Wilson IA
Science; 2001 Aug; 293(5532):1155-9. PubMed ID: 11498595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
